These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 32000630)

  • 1. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial.
    Qamar A; Morrow DA; Creager MA; Scirica BM; Olin JW; Beckman JA; Murphy SA; Bonaca MP
    Vasc Med; 2020 Apr; 25(2):124-132. PubMed ID: 32000630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial.
    Bonaca MP; Creager MA; Olin J; Scirica BM; Gilchrist IC; Murphy SA; Goodrich EL; Braunwald E; Morrow DA
    JACC Cardiovasc Interv; 2016 Oct; 9(20):2157-2164. PubMed ID: 27765312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of vorapaxar as approved for clinical use in the United States.
    Magnani G; Bonaca MP; Braunwald E; Dalby AJ; Fox KA; Murphy SA; Nicolau JC; Oude Ophuis T; Scirica BM; Spinar J; Theroux P; Morrow DA
    J Am Heart Assoc; 2015 Mar; 4(3):e001505. PubMed ID: 25792124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
    Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW
    Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50).
    Bonaca MP; Gutierrez JA; Creager MA; Scirica BM; Olin J; Murphy SA; Braunwald E; Morrow DA
    Circulation; 2016 Mar; 133(10):997-1005. PubMed ID: 26826179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.
    Bohula EA; Bonaca MP; Braunwald E; Aylward PE; Corbalan R; De Ferrari GM; He P; Lewis BS; Merlini PA; Murphy SA; Sabatine MS; Scirica BM; Morrow DA
    Circulation; 2016 Jul; 134(4):304-13. PubMed ID: 27440003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2°P-TIMI 50 trial.
    Patel SM; Morrow DA; Kidd SK; Goodrich EL; Scirica BM; Bonaca MP
    Vasc Med; 2019 Apr; 24(2):159-161. PubMed ID: 30868939
    [No Abstract]   [Full Text] [Related]  

  • 8. Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar.
    Déry JP; Mahaffey KW; Tricoci P; White HD; Podder M; Westerhout CM; Moliterno DJ; Harrington RA; Chen E; Strony J; Van de Werf F; Ziada KM; Held C; Aylward PE; Armstrong PW; Rao SV
    Catheter Cardiovasc Interv; 2016 Aug; 88(2):163-73. PubMed ID: 26698636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial.
    Gilchrist IC; Morrow DA; Creager MA; Olin JW; Scirica BM; Goodrich EL; Bonaca MP
    J Am Heart Assoc; 2021 Oct; 10(20):e021412. PubMed ID: 34622665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease.
    Morrison JT; Govsyeyev N; Hess CN; Bonaca MP
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484211056115. PubMed ID: 35006035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.
    Bonaca MP; Scirica BM; Creager MA; Olin J; Bounameaux H; Dellborg M; Lamp JM; Murphy SA; Braunwald E; Morrow DA
    Circulation; 2013 Apr; 127(14):1522-9, 1529e1-6. PubMed ID: 23501976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vorapaxar in the secondary prevention of atherothrombotic events.
    Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
    N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of vorapaxar in patients with prior ischemic stroke.
    Morrow DA; Alberts MJ; Mohr JP; Ameriso SF; Bonaca MP; Goto S; Hankey GJ; Murphy SA; Scirica BM; Braunwald E;
    Stroke; 2013 Mar; 44(3):691-8. PubMed ID: 23396280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial.
    Gutierrez JA; Mulder H; Jones WS; Rockhold FW; Baumgartner I; Berger JS; Blomster JI; Fowkes FGR; Held P; Katona BG; Mahaffey KW; Norgren L; Hiatt WR; Patel MR
    JAMA Netw Open; 2018 Nov; 1(7):e185239. PubMed ID: 30646395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic treatment in peripheral artery disease.
    Olinic DM; Tataru DA; Homorodean C; Spinu M; Olinic M
    Vasa; 2018 Feb; 47(2):99-108. PubMed ID: 29160765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial.
    Bonaca MP; Scirica BM; Braunwald E; Wiviott SD; Goto S; Nilsen DW; Bonarjee V; Murphy SA; Morrow DA
    J Am Coll Cardiol; 2014 Dec; 64(22):2318-26. PubMed ID: 25465417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vorapaxar: A Protease-Activated Receptor Antagonist for the Prevention of Thrombotic Events.
    Lam S; Tran T
    Cardiol Rev; 2015; 23(5):261-7. PubMed ID: 25923910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50.
    Kidd SK; Bonaca MP; Braunwald E; De Ferrari GM; Lewis BS; Merlini PA; Murphy SA; Scirica BM; White HD; Morrow DA
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27431644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotics in stable peripheral artery disease.
    Kaplovitch E; Rannelli L; Anand SS
    Vasc Med; 2019 Apr; 24(2):132-140. PubMed ID: 30799766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials.
    Bauersachs R; Wu O; Briere JB; Bowrin K; Borkowska K; Jakubowska A; Taieb V; Toumi M; Huelsebeck M
    Cardiovasc Ther; 2020; 2020():3057168. PubMed ID: 32695228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.